[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-400461-105":59,"doc-detail-400461-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","croi-2023-doxycycline-pepprep-abstracts","CROI 2023 Doxycycline PEP/PrEP Abstracts","","CROI 2023 abstract collection on doxycycline-based STI prevention, covering doxycycline postexposure prophylaxis (PEP) and doxycycline preexposure prophylaxis (PrEP) approaches. It reports an open-label randomized trial in cisgender women in Kisumu, Kenya, evaluating incident Chlamydia trachomatis, Neisseria gonorrhoeae, and Treponema pallidum infections, alongside findings from mucosal pharmacology studies measuring doxycycline concentrations in rectal, vaginal, cervical, and urethral compartments. The set also describes doxycycline use in MSM on PrEP for prevention of sexually transmitted infections.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/croi-2023-doxycycline-pepprep-abstracts/400461/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/croi-2023-doxycycline-pepprep-abstracts/400461.png","ImageObject",300,407,{"name":92,"@type":93},"Đào","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-27",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was tested in the trial of doxycycline PEP among cisgender women?","Question",{"text":112,"@type":113},"The study tested doxycycline hyclate 200 mg taken within 72 hours of sex versus standard of care, using incident C. trachomatis, N. gonorrhoeae, or T. pallidum infections measured over one year.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was doxycycline distribution assessed in the mucosal pharmacology study?",{"text":117,"@type":113},"Participants received a 200 mg oral doxycycline dose, and blood plus mucosal specimens were collected to measure doxycycline concentrations and time above MIC90 for relevant pathogens.",{"name":119,"@type":110,"acceptedAnswer":120},"What overall conclusion was reached about doxycycline PEP effectiveness in the women’s study?",{"text":121,"@type":113},"Among young cisgender women with high STI prevalence and incidence, doxycycline PEP after sex did not reduce incident STIs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},400461,1790673622,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","CROI Doxycycline PEP/PrEP Abstracts  \n1. Doxycycline Postexposure Prophylaxis for Prevention of STIs Among Cisgender Women  \nJenell Stewart, Kevin Oware, Deborah Donnell, Lauren R.Violette, Josephine Odoyo, Caitlin  \nW.Scoville, Olusegun O.Soge, Victor Omollo, Felix Mogaka, Fredricka A.Sesay, R. Scott  \nMcClelland, Elizabeth A. Bukusi, Jared M. Baeten  \nBackground:  \nBacterial sexually transmitted infections (STIs) are repsonsible for significant and disproportionate morbidity and mortality in cisgender women, among whom STI incidence has been rising globally. Doxycycline taken as postexposure prophylaxis (PEP) was efficacious at preventing STIs among cisgender men who have sex with men and transgender women, but no trials among cisgender women have been done.  \nMethods:  \nWe conducted an open-label randomized trial of doxycycline PEP (doxycycline hyclate 200mg taken within 72 hours of sex) compared with standard of care (e.g., quarterly screening and treating STIs) among women aged 18-30 years in Kisumu, Kenya. Participants were required to already be taking daily oral HIV preexposure prophylaxis (PrEP) . Contraception was not required, and doxycycline was stopped during pregnancy. Weekly SMS surveys were done to assess concomitant doxycycline PEP use with sex. The primary endpoint was any incident Chlamydia trachomatis, Neisseria gonorrhoeae, or Treponema pallidum infection, measured quarterly for one year; the trial had 80% power to detect 50% reduction in incident STIs, anticipating 66 incident STIs.  \nResults:  \nWe enrolled 449 cisgender women; women completed 97% of expected follow-up visits. Median age was 24 years (IQR 21-27), 36.7% reported transactional sex at enrollment, and baseline STI prevalence was 17.9%(14 . 1% C. trachomatis, 3.8% N. gonorrhoeae, 0.4% T.  \npallidum) . Incident STI events were detected at 109 follow up visits (85 C. trachomatis, 31 N. gonorrhoeae, including 8 with both; 1 T. pallidum): 50 among those assigned to doxycycline PEP and 59 among those assigned STI screening and treatment alone (RR 0 .88, 95% CI 0.60-1. 29, p=0 .51) . Analysis with follow-up time censored once participants became pregnant (n=80), analysis of each STI separately, and subgroup analyses (including by age, contraceptive use, transactional sex, and STI detected at baseline) found similar results. There were no serious adverse events determined to be related to use of doxycycline. No incident HIV infections were  \ndetected. Weekly SMS surveys had an overall 81% response rate, and women assigned to PEP reported taking doxycycline PEP at least as many days they had sex in 78% of surveys.  \nConclusions:  \nAmong young cisgender women with high prevalence and incidence of STIs, the use of doxycycline PEP following sex did not reduce incident STIs.  \nDoxycycline Postexposure Prophylaxis for Prevention of STIs Among Cisgender Women  \n2. Mucosal Pharmacology of Doxycycline for Bacterial STI Prevention in Men and Women  \nRichard Haaland, Jeffrey Fountain, Chuong Dinh, Tiancheng Edwards, Amy Martin, Deborah Omoyege, Christopher Conway-Washington, Colleen Kelley, Walid Heneine  \nBackground:  \nOral doxycycline (DOX) prophylaxis is a promising strategy to prevent bacterial sexually transmitted infections (STIs) . Clinical trials demonstrated a 200 mg oral DOX dose taken by men who have sex with men (MSM) after sexual exposure can provide protection against STIs. However, mucosal pharmacokinetic data at the site of STI exposure and DOX activity are lacking. We examined mucosal DOX concentrations in men and women to better understand DOX efficacy and inform dose optimization for STI prevention.  \nMethods:  \nEleven male and 9 female participants provided blood and mucosal swabs up to 7 days after receiving a 200 mg oral DOX dose. Rectal, vaginal and cervical biopsies as well as urethral swabs were collected 24 hours after dosing. DOX was measured by liquid chromatography-mass spectrometry with a lower limit of quantification of 10 ng/mL f","cbCaiqaB4NYYtdye","https://ap.wps.com/l/cbCaiqaB4NYYtdye","pdf",272247,"English","# CROI Doxycycline PEP/PrEP Abstracts\n## Doxycycline Postexposure Prophylaxis for Prevention of STIs Among Cisgender Women\n## Mucosal Pharmacology of Doxycycline for Bacterial STI Prevention in Men and Women\n## Daily Doxycycline in MSM on PrEP for Prevention of Sexually Transmitted Infections","[{\"question\":\"What was tested in the trial of doxycycline PEP among cisgender women?\",\"answer\":\"The study tested doxycycline hyclate 200 mg taken within 72 hours of sex versus standard of care, using incident C. trachomatis, N. gonorrhoeae, or T. pallidum infections measured over one year.\"},{\"question\":\"How was doxycycline distribution assessed in the mucosal pharmacology study?\",\"answer\":\"Participants received a 200 mg oral doxycycline dose, and blood plus mucosal specimens were collected to measure doxycycline concentrations and time above MIC90 for relevant pathogens.\"},{\"question\":\"What overall conclusion was reached about doxycycline PEP effectiveness in the women’s study?\",\"answer\":\"Among young cisgender women with high STI prevalence and incidence, doxycycline PEP after sex did not reduce incident STIs.\"}]","CROI 2023 Doxycycline PEP/PrEP Abstracts | PDF",1790511646,25]